Cargando…

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study

SUMMARY: A 48-week, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial (the TWICE study) conducted in Japanese primary osteoporosis patients with a high risk of fractures demonstrated that a 28.2-μg twice-weekly regimen of teriparatide can provide comparabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, T., Shiraki, M., Fukunaga, M., Kishimoto, H., Hagino, H., Sone, T., Nakano, T., Ito, M., Yoshikawa, H., Minamida, T., Tsuruya, Y., Nakamura, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811384/ https://www.ncbi.nlm.nih.gov/pubmed/31392401 http://dx.doi.org/10.1007/s00198-019-05111-6

Ejemplares similares

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
por: Sugimoto, Toshitsugu, et al.
Publicado: (2021)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT
por: Ito, M., et al.
Publicado: (2013)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
por: Hagino, H., et al.
Publicado: (2021)

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
por: Fujita, Ryo, et al.
Publicado: (2022)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
por: Sugimoto, T., et al.
Publicado: (2013)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy
por: Nakayama, Harumi, et al.
Publicado: (2018)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide
por: Tanaka, Sakae, et al.
Publicado: (2014)

Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis
por: Fujita, Takuo, et al.
Publicado: (2013)

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1
por: Best, J H, et al.
Publicado: (2009)

Is Twice-weekly Maintenance Hemodialysis Justified?
por: Mendonca, Satish, et al.
Publicado: (2021)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Measure Twice, Cut Once
por: D’Alessandro, David A., et al.
Publicado: (2021)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
por: Takeuchi, Yasuhiro, et al.
Publicado: (2015)

Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study
por: OHTA, SHOICHIRO, et al.
Publicado: (2014)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Feasibility of Twice-Weekly Hemodialysis During COVID-19
por: Siga, Esteban
Publicado: (2021)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial
por: Javadi, Amir, et al.
Publicado: (2022)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

A Comparison of Practice Pattern and Outcome of Twice-weekly and Thrice-weekly Hemodialysis Patients
por: Mukherjee, T., et al.
Publicado: (2017)

Feasibility of Twice-Weekly Hemodialysis: Contingency Planning for COVID-19
por: Clark, David A., et al.
Publicado: (2021)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Effectiveness of Weekly Teriparatide Injection in Postmenopausal Patients with Hip Fractures
por: Lee, Sang Yeob, et al.
Publicado: (2023)

Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice‐Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single‐Blind Randomized Study
por: Kumagai, Yuji, et al.
Publicado: (2019)

Preference and Expectation for Treatment Assignment in a Randomized Controlled Trial of Once- vs Twice-weekly Yoga for Chronic Low Back Pain
por: Tran, Huong H., et al.
Publicado: (2015)

Cost-effectiveness of twice-weekly versus once-weekly sessions of cognitive–behavioural therapy and interpersonal psychotherapy for depression at 12 months after start of treatment: randomised controlled trial
por: Bosmans, Judith E., et al.
Publicado: (2023)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
por: Lee, Joo-Heung, et al.
Publicado: (2016)

Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
por: Moriwaki, K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rvkpqbfs3tgus0he3oekp52024